Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 4/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923871 | 1.00 | GRIN1 (0.49) | GRIN1GRIN2BFFAR4CHRNA7CHRM4 | |
| SCHEMBL23924382 | 0.84 | GRIN1 (0.48) | GRIN1GRIN2BCHRM4P2RY14 | |
| SCHEMBL23924384 | 0.84 | GRIN1 (0.48) | GRIN1GRIN2BCHRM4P2RY14 | |
| SCHEMBL23951715 | 0.84 | PIK3CD (0.46) | GRIN1GRIN2BFFAR4KMT2A | |
| SCHEMBL26933497 | 0.81 | LIPE (0.44) | — | |
| SCHEMBL26933503 | 0.81 | LIPE (0.44) | — | |
| SCHEMBL23924232 | 0.80 | EPHX2 (0.48) | FFAR4KMT2A | |
| SCHEMBL23924231 | 0.80 | EPHX2 (0.48) | FFAR4KMT2A | |
| SCHEMBL23924049 | 0.80 | EPHX2 (0.51) | GRIN1GRIN2BOPRM1OPRK1KCNH2 | |
| SCHEMBL23924051 | 0.80 | EPHX2 (0.51) | GRIN1GRIN2BOPRM1OPRK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S.R.L. (IT) | 2022-07-07 | — | — | US | disclosed |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | TES PHARMA S R L (IT) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213061-A9 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | GRIN1 81/4885GRIN2B 80/4885FFAR4 2242/4885 |
| US-20210323942-A1 | HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 | NR2E3, NR2F2, NR2C2 | GRIN1 81/4885GRIN2B 80/4885FFAR4 2242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.